Mandate

Bravida listed on Nasdaq Stockholm

October 22, 2015

Bravida Holding AB (publ) has on 16 October 2015 been admitted to trading on Nasdaq Stockholm. The price in the offering was set at SEK 40 per share, corresponding to a market value of all shares issued by Bravida of SEK 8.1 billion. The offer, which consisted of an offer to the general public in Sweden and an international offer to institutional investors, comprised in total 40.5 percent of the Bravida shares offered by Bravissima Holding AB, Bravida´s principal owner, which is indirectly controlled by certain investment funds advised by Bain Capital, LLC and affiliated parties. The total value of the offering amounts to SEK 3.2 billion, assuming that the over-allotment option is exercised in full.

Bravida is a leading provider of multi-technical services within electricity, heating and plumbing as well as ventilation and air conditioning in the Nordic region. With 237 branches across 140 locations, Bravida offers installation and services solutions throughout the Nordic region with strong local presence. For the year ended 31 December 2014, Bravida recorded net sales of SEK 12 billion.

Bravida and Bravissima Holding AB were advised by Vinge in connection with the listing and Vinge’s team mainly consisted of Charlotte Levin, Christina Kokko, Louise Brorsson Salomon, Nicolina Kindblom, Rikard Lindahl, Nils Fredrik Dehlin, Emelie Klefbeck, Filip Öhrner, Linn Adelwald and Samra Baytar. Further, Odile Fallenius, Maria Schultzberg and Tora Hansjons have assisted with tax related matters.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025